(Q34373712)

1 August 2017

1 reference

title

Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation (English)

1 reference

1 August 2017

1 reference

White CM

1

1 reference

1 August 2017

publication date

1 February 1999

1 reference

The Journal of Clinical Pharmacology

1 August 2017

published in

1 reference

1 August 2017

volume

39

1 reference

1 August 2017

issue

2

1 reference

1 August 2017

page(s)

111-118

1 reference

Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings?

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Statins do more than just lower cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Endothelial vasodilator dysfunction: pathogenetic link to myocardial ischaemia or epiphenomenon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

The pathogenesis of atherosclerosis: a perspective for the 1990s

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Replication of smooth muscle cells in vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Is vascular smooth muscle cell proliferation beneficial?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Directional atherectomy for treatment of restenosis within coronary stents: clinical, angiographic and histologic results

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Molecular bases of the acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Fibrinogen and risk of cardiovascular disease. The Framingham Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Plasma fibrinogen: a new factor of the metabolic syndrome. A population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Fibrinogen is an independent marker for thoracic aortic atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Simvastatin in non-insulin-dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Simvastatin in severe hypercholesterolaemia: a placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

The effect of pravastatin on acute rejection after kidney transplantation--a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Effect of pravastatin on outcomes after cardiac transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. The Lovastatin Pravastatin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. The Simvastatin Pravastatin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Disease-free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia: report from the Program on the Surgical Control of the Hyperlipidemias (POSCH)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Close relation of endothelial function in the human coronary and peripheral circulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Reversing endothelial dysfunction with ACE inhibitors. A new trend

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Postischemic blood flow response in hypercholesterolemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Pathogenesis of atherosclerosisand the role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Proliferation in primary and restenotic coronary atherectomy tissue. Implications for antiproliferative therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Platelet-dependent thrombin generation in patients with hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Fibrinogen, coronary heart disease and mortality from all causes in smokers and nonsmokers. The study of men born in 1933

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Restenosis after elective coronary balloon angioplasty in patients with end stage renal disease: a case-control study using quantitative coronary angiography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Effect of atorvastatin on plasma fibrinogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Lovastatin therapy in hypercholesterolemia: effect on fibrinogen, hemorrheologic parameters, platelet activity, and red blood cell morphology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Abnormalities of blood rheology in familial hypercholesterolaemia: effects of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922007642

10.1177/00912709922007642

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference